Stay updated on AB680 Safety in Gastrointestinal Malignancies Clinical Trial
Sign up to get notified when there's something new on the AB680 Safety in Gastrointestinal Malignancies Clinical Trial page.

Latest updates to the AB680 Safety in Gastrointestinal Malignancies Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedRevision label on the page updated to v3.5.4 from v3.5.3, indicating a new version of the page content.SummaryDifference0.0%

- Check27 days agoChange DetectedNew site entry 'Research Site' added on 2026-05-07 to the study's list of participating locations, and a number of established centers were removed (e.g., The Angeles Clinic, UCLA Hematology Oncology, NYU Cancer Institute, Memorial Sloan Kettering, MD Anderson, START San Antonio, UW Carbone Cancer Center). These changes alter where patients can enroll and who is involved in the ARC-8 trial.SummaryDifference0.7%

- Check34 days agoChange DetectedA new Nat Med publication citation for the trial has been added to Publications. The previous 'Online ahead of print' citation has been removed.SummaryDifference0.0%

- Check41 days agoChange DetectedThe revision/version identifier in the page footer has been updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check48 days agoChange Detected- Revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a Publications section with Quemliclustat and zimberelimab in metastatic pancreatic adenocarcinoma (Nat Med 2026) and PubMed notes. Updated Locations: removed Medical Oncology Associates (Spokane) and changed total locations from 14 to 13.SummaryDifference0.5%

Stay in the know with updates to AB680 Safety in Gastrointestinal Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AB680 Safety in Gastrointestinal Malignancies Clinical Trial page.